Company intelligence / Profile preview

Origins Life Sciences

Princeton, New Jersey, United Stateswis-wander.weizmann.ac.il ↗

Ownership: Private
Employees: ~7
Development stage: Other

Overview

Origin Life Sciences has completed a dose-ranging feasibility clinical trial for diabetic foot ulcers using its IonoJet™ plasma/NO device and is preparing for a pivotal clinical trial. The technology has shown the ability to generate nitric oxide activity up to 3 cm below the skin and stimulate sustained biological activity in tissue for up to an hour after delivery.

Therapeutic areas: DermatologyEndocrinologyInfectious Diseases
Modalities: DeviceNitric oxide-based therapyPlasma-based therapy
Industry: Therapeutic Medical Devices

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Origins Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Origins Life Sciences.

Explore the full profile